Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Thursday, February 7, 2013

Chronic Hepatitis Cohort Study Sheds Light on Burden of Hepatitis B and C in U.S.

People born between 1945 and 1964 account for the highest proportion of hepatitis B and C cases, and these viruses are a significant cause of illness and death, according to an analysis described in the January 1, 2013, Clinical Infectious Diseases...Approximately 1.25 million people in the U.S. are thought to carry chronic hepatitis B, while estimates for chronic hepatitis C fall with in the 3-4 million range. But the disease progression and the clinical implications of these viruses in the "real world" are not fully known.

Over years or decades chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection can lead to advanced liver disease including cirrhosis (scarring) and hepatocellular carcinoma.  Hepatitis B can be prevented with an effective vaccine, but complete cures are uncommon. Hepatitis C, in contrast, currently has no vaccine but treatment is increasingly effective at curing infection.

Read more here...

No comments:

Post a Comment